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ABSTRACT
Neurodegenerative disorders involve complexities of the pathologies, characterized by the progressive loss of neuronal viability, leading to severe 
physical and cognitive impairments in affected patients. These disorders although may differ in clinical outcomes yet they share common features 
such as aggregation of neurotoxic metabolites and perturbed cellular and neuronal homeostasis. Mitochondrion is an indispensable organelle for 
neuronal survival, and its role and place have become critical in research arena of aging and neurodegenaration. The accumulation of damaged 
mitochondria has been linked to normal aging and multiple age-related disorders including Alzheimer’s disease (AD). Survival and proper function 
of mitochondria depend on several attributes that include mitochondrial biogenesis and fusion and fission. Mitophagy is an utmost requirement 
for degradation and removal of damaged mitochondria where the target mitochondria are identified by the autophagosomes and delivered to the 
lysosome for degradation. Mitophagy plays important roles in mitochondrial homeostasis, neuroprotection, and resistance to neurodegeneration. 
AD besides other characteristic features involves mitochondrial dysfunctional, bioenergetic deficit, and altered mitophagy. The autophagy/lysosome 
pathway that removes damaged mitochondria (mitophagy) is compromised in AD, resulting in the accumulation of dysfunctional mitochondria that 
contribute to synaptic dysfunction and cognitive deficits by triggering Aβ and Tau accumulation through increases in oxidative damage and cellular 
energy deficits. The present work reviews the various implications of mitophagy in relevance to the pathology of AD.
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INTRODUCTION
The expansion of the mitochondrial research is attributable to the 
convergence of key signaling pathways and biological processes onto 
the mitochondrion and their relevance to different pathologies [1]. As 
life evolved from unicellular organisms over the past 1.2–1.5 billion 
years and mitochondria played a permissive role in the evolution of 
multicellular organisms [2], mitochondria are intimately linked to a 
number of basic cellular and physiological functions [3].
The origin of mitochondria in the eukaryotic cell is traced back to the 
merger of two cells. Billions of years ago, the mitochondrion developed 
from an α-proteobacterium that was taken up by a host cell providing 
an evolutionary advantage which kept it alive. Different theories exist 
to whether the host cell was of eukaryotic origin or a prokaryotic and 
later theory being favored. Over time, most of the bacterial genome was 
transferred to the genome of the host, but a small percentage remained 
in the mitochondrion, and thus, mitochondrial machinery is encoded 
by two genomes in separate compartments within the same cell, the 
mitochondrial DNA (mtDNA) and the nuclear DNA (nDNA) [2,4].
The mitochondrion is formed by two phospholipid bilayers enclosing 
the mitochondrial matrix. The outer mitochondrial membrane faces 
the cytosol and is permeable to metabolites required for mitochondrial 
function. The inner mitochondrial membrane, in contrast, tightly 
regulates the transport of even the smallest ions, the smallest being the 
hydrogen ion which eventually drives phosphorylation of adenosine 
diphosphate (ADP) to adenosine triphosphate (ATP). The inner 
mitochondrial membrane is highly folded to further increase its surface 
area which forms cristae, the regions at which mitochondrial ATP is 
generated.
The mitochondrion is highly versatile, dynamic and has multiple 
functions. It can buffer calcium and, in doing so, maintains cytosolic 
and mitochondrial calcium levels to regulate the diverse set of cellular 
enzymatic reactions. It also regulates metabolite levels to provide 
precursors for the synthesis of amino acids, nucleotides, and fatty acids 
and is involved in the cellular response to stress [5]. Mitochondria 
are also crucial in apoptosis, necrosis, autophagy, stress regulation, 
production of lipids and carbohydrates, Ca2+ storage, and innate 
immunity [6].
Diseases specifically linked to mitochondrial dysfunction vary 
from the well known (glaucoma, inflammation, neurodegenerative 
diseases (NDs), type 2 diabetes, cancers, especially those involving 
prostate and colon, cardiomyopathies, and dysrhythmias) to the 
less well known (Friedreich’s ataxia) to a group of relatively obscure 
disease states (Kearns-Sayre syndrome, Leber’s hereditary optic 
neuropathy, mitochondrial encephalopathy, lactic acidosis, and 
strokes, myoclonic epilepsy with ragged red fibers, and mitochondrial 
neurogastrointestinal encephalomyopathy [7]. Deficiencies in 
energy metabolism and bioenergetic failure are characteristic of 
mitochondrial and epigenomic disease states [8] and have been 
implicated in a variety of human disease states, especially in organs 
where there is a high level of energy consumption, for example, the 
brain. The brain, with only 2% of total body weight, represents 20% 
of the total oxygen consumption in the body.
Mitochondria and energy production
The primary function of the mitochondrion is to produce energy which 
it produces in the form of ATP through a process referred to as oxidative 
phosphorylation (OXPHOS). The energy stored in carbohydrates, fats, 
and proteins is broken down to generate high-energy electrons which 
are carried down a chain of protein complexes at the inner mitochondrial 
membrane, the respiratory chain. This electron transport is coupled to 
proton pumping across the inner mitochondrial membrane, generating 
a proton gradient which is used by the ATP synthase, also known as 
complex V (CV), to phosphorylate ADP [9,10].
Human mtDNA is approximately 16.6 base pairs long, forming a 
closed, double-stranded structure [11 ]. Each mitochondrion contains 
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between 2 - 10 mtDNA copies that consist of 37 genes which encodes 22 
transfer, 2 ribosomal DNAs and 13 proteins. The proteins thus encoded 
include the enzymes which are involved in the OXPHOS pathway for 
ATP production. OXPHOS units are coded by both nDNA and mtDNA, 
with the former contributing somewhere in excess of 1000 proteins 
that are essential for mitochondrial function [8,12]. Of these, 705 are 
under the transcriptional control of estrogen-related receptors that are 
responsible for the integrated control of mitochondrial metabolism [12].
The OXPHOS pathway consists of five different electron transport 
chain (ETC) complexes located on the inner mitochondrial membrane 
that together contributes to the generation of the mitochondrial 
electrochemical gradient. These complexes are composed of proteins 
that originate from both nDNA and mtDNA [8,13]. Complex I consists 
of 45 peptide subunits, 7 originating from mtDNA with the remainder 
from nDNA. Complex II has four subunits, all of which are derived from 
nDNA, and Complex III has 11 subunits, only one of which originates 
from mtDNA. Complex IV has 12 subunits, 3 of which are derived from 
mtDNA, and complex IV has approximately 16 subunits, 2 of which are 
from mtDNA. The fifth ETC complex, CV, is ATP synthase [14].
Approximately 90% of ATP arises from mitochondria. In complex I 
(β-nicotinamide adenine dinucleotide (NADH) dehydrogenase), two 
electrons are removed from NADH and transferred to the lipid-soluble 
carrier, ubiquinone (Q) forming the reduced product, ubiquinol (QH 2) 
that can freely diffuse in the membrane. Complex I thus leads to the 
translocation of four protons across the membrane to produce a proton 
gradient.
In complex II (succinate dehydrogenase), additional electrons are 
delivered from succinate through flavin adenine dinucleotide (FAD) to 
the quinone pool (Q) and transferred through FAD to Q. In complex III 
(QH-cytochrome c [CytC] reductase), six electrons are removed from 
QH 2, two of which are sequentially transferred to two molecules of 
CytC, a water-soluble electron carrier located in the intermembrane 
space, and four to the Qi site where the quinone moiety in ubiquinone 
is reduced to quinol contributing to the proton gradient. In complex IV 
(CytC oxidase), four electrons contributed by four CytC molecules are 
transferred to molecular oxygen (O2), resulting in two molecules of 
water. Concomitantly, four protons translocate across the membrane, 
adding further to the proton gradient. The latter is then used in CV, the 
F 0/F 1 ATP synthase complex to produce ATP through OXPHOS [15].
Mutation rates in mtDNA are generally 2-3-fold higher than those 
occurring in nDNA due to consequence of the proximity of mtDNA to 
the reactive oxygen species (ROS) produced by electron leakage from 
complexes I and III of the ETC. The scenario is further complicated with 
inefficient DNA repair mechanisms and a lack of protective histones on 
mtDNA which are thought to affect mitochondrial protein synthesis, 
protein-encoding genes and mRNA, and ultimately mitochondrial 
function. These are complemented by rearrangements, deletions, and 
insertions in mtDNA and their altered interactions with nDNA, the latter 
reflecting defects in mitochondrial transport processes [13]. Thus, the 
age-related accumulation of somatic mtDNA mutations that can lead 
in time to decreased mitochondrial function has been associated with 
an increased rate of aging [8,16,17]. A variety of conditions (hypoxia, 
stress, trauma, blood glucose levels, aberrant circadian rhythms, etc.) and 
agents/mechanisms (phosphorylation, DNA methylation/acetylation, 
Akt/protein kinase B signaling, calcium homeostasis, estrogen-related 
receptor signaling, heat shock proteins, soluble adenylyl cyclase, receptor-
interacting protein 3 kinase, target of rapamycin kinases, peroxisome 
proliferator-activated receptor-α, adenosine monophosphate-
activated protein kinase, β-amyloid, sirtuin-1, etc.) are involved in both 
modulating transcription of the mitochondrial genome and the function 
of the transcribed proteins. Mutated proteins such as huntingtin in HD; 
amyloid (Aβ) in Alzheimer’s disease (AD); superoxide dismutase (SOD) 
1 in amyotrophic lateral sclerosis; and parkin, DJ1, and α-synuclein in 
Parkinson’s disease have been localized to mitochondrial membranes [18] 
where they can alter ETC function to increase ROS production [14].
MITOCHONDRIAL DYNAMICS
Aging, at the cell level, is an increasingly incapacity to recycle organelles 
and macromolecules. High-energy requirement tissues such as the brain 
are highly dependent on mitochondria. In a single neuron, hundreds to 
thousands of mitochondria are contained [19].
Mitochondria form networks throughout the cell through the opposing 
processes of fission and fusion [20]. The latter is critical to the 
maintenance of mitochondrial function because it affects the repair of 
dysfunctional and damaged mitochondria in addition to intermixing 
DNA and proteins between mitochondria [21]. Fusion involves the 
merging of the inner and outer membranes from two mitochondria 
to facilitate the GTPase-dependent exchange of materials to aid in 
mitochondrial repair. Fission occurs when a mitochondrion splits in 
two. When this process occurs in the presence of decreased fusion, it 
can lead to a fragmented mitochondrial phenotype that is widespread 
in both necrosis and apoptosis. Deficient fission and fusion mechanisms 
are, thus, key events in mitochondrial disease causality [14].
In aging, proteasome activity decreases, autophagy is impaired, and 
mitochondrial dysfunction emerges with a decrease of OXPHOS, beta-
oxidation, and Krebs cycle as well as an increase of oxidative stress that, 
in turn, damages mitochondria.
As the age progresses, vulnerability of mitochondria also increases. 
Aging is tightly linked to mtDNA deletions, point mutations, and ROS. 
In addition, mtDNA deletions and point mutations accumulate over 
time. This leads to energetics impairment, increased ROS production, 
mtDNA lesions, and the decline of mitochondrial respiration. ROS 
targets mtDNA since there are no histones and efficacious proofreading 
systems and this brings more point mutations and deletions. In the 
mitochondria, deletions expand clonally over time and their number 
correlates linearly with the cell age [22].
ROS and brain
OXPHOS occurring in the mitochondria is a major source of ATP, but 
the by-product of this process is free radicals or ROS, reactive nitrogen 
species (RNS), and carbon- and sulfur-centered radicals [23]. Low 
amounts of ROS are considered essential for neuronal development 
and function, as ROS-generated nitrous oxide and carbon monoxide 
promote important physiologic functions, such as long-term 
potentiation (LTP) via glutamate-dependent mechanisms [24,25].
Under normal conditions, deleterious effects of ROS production during 
aerobic metabolism are neutralized by the antioxidant system, and in 
this manner, the brain effectively regulates its oxygen consumption 
and redox generation capacity. When ROS production exceeds the 
scavenging capacity of antioxidant response system, extensive protein 
oxidation and lipid peroxidation occur, causing oxidative damage, 
cellular degeneration, and even functional decline. For example, high 
ROS concentrations reportedly diminish LTP and synaptic signaling and 
brain plasticity mechanisms [24-26].
The brain, with its rich lipid content, high-energy demand, and weak 
antioxidant capacity, becomes an easy target of excessive oxidative 
insult. Phospholipids in the brain are particularly vulnerable entities 
for ROS-mediated peroxidation, but proteins and DNA also are targeted 
by ROS, which becomes particularly problematic during aging, as aged 
brains have been reported to exhibit high levels of oxidative stress-
induced mutations in the mtDNA [27-29]. Therefore, ROS accumulation 
is a cellular threat that, if it exceeds or bypasses counteracting 
mechanisms, can cause significant neuronal damage [29].
Two kinds of protective mechanisms operate in the brain to tackle 
the threat posed by ROS, the antioxidant enzyme system and the low-
molecular-weight antioxidants [30,31]. The antioxidant enzyme system 
includes SOD, glyoxalase, glutathione reductase, glutathione peroxidase 
(GPx), and catalase (CAT). SOD enzymes, including Cu-Zn SOD and 
Mn-SOD, facilitate spontaneous dismutation of superoxide radicals to 
generate H2O2, which is further removed by CAT and GPx enzymes [32]. 
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The low-molecular-weight antioxidants include glutathione, uric acid, 
ascorbic acid, and melatonin, which offer neutralizing functions by 
causing chelation of transition metals [33].
In response to oxidative and nitrosative stress, cells increase their 
antioxidant defenses through activation of nuclear factor erythroid 
2-related factor (Nrf2), an important transcription factor [34]. 
Nrf2 is a key component of this control system and recognizes the 
antioxidant response element found in the promoter regions of many 
genes that encode antioxidants and detoxification enzymes such as 
heme oxygenase 1 (HO-1), NAD(P)H dehydrogenase quinone 1, SOD1, 
GPx1, and CAT. Thus, Nrf2 pathway activation occurs to combat the 
accumulation of ROS and RNS species. Due to its protective properties, 
Nrf2 has been proposed as a pharmacological target in pathologies with 
neuroinflammatory and oxidative features, including neurodegenerative 
and neuropsychiatric diseases. When activated, Nrf2 increases the 
expression of several endogenous antioxidants. Moreover, on persistent 
inflammation and increased ROS levels, as observed during several 
psychiatric episodes, tissue antioxidant defense mechanisms are 
saturated to the point they become ineffective [26,34].
Mechanisms by which ROS causes cerebral tissue damage are not 
well understood, but ROS is reported to trigger a variety of molecular 
cascades that increase blood–brain barrier permeability and alter brain 
morphology, thus causing neuroinflammation and neuronal death [35]. 
Involvement of hypothalamic-pituitary-adrenal axis-mediated 
glucocorticoid receptor signaling, glutamate toxicity, and N-methyl-D-
aspartate receptor signaling systems also has been suggested [36,37].
Biochemically, it is evident that different neurons have different levels of 
vulnerability to oxidative stress. For example, hippocampus, amygdala, 
and cerebellar granule cells have been reported as the most susceptible 
to oxidative stress in some studies [38], and cognitive deficits are 
attributed to these regions [39,40]. Hippocampus seems to be at the hot 
seat, and it appears that this brain region undergoes major biochemical 
changes that ultimately determine neuronal connections and function. 
Within the hippocampus, it is well known that the dentate gyrus 
(DG)–cornu ammonis (CA) 3 system exhibits structural plasticity with 
regenerative/remodeling capacity [41]. Furthermore, several studies 
have suggested that pyramidal cells of CA3 and granule cells of the DG 
are oxidative stress-prone areas, whereas others have suggested that 
pyramidal cells of CA1 are more susceptible to oxidative damage [42,43].
AUTOPHAGY
Autophagy is an evolutionarily conserved process, in which cytoplasmic 
substrates are engulfed in an autophagic vesicle, fused to lysosomes, 
and degraded. Autophagy is a self-elimination process through which 
cells degrade their own components while recycling amino acids and 
other building parts that can eventually be reused.
Autophagy is a cellular degradation process in which cytosolic 
cargos are degraded by lysosomes and it can be divided into three 
subtypes - microautophagy, chaperone-mediated autophagy, and 
macroautophagy. In microautophagy, cytosolic cargo is directly 
engulfed by the lysosome through invagination of the lysosomal 
membrane, whereas in chaperone-mediated autophagy, cargo is 
selectively recognized by cytosolic chaperones that deliver the cargo to 
a translocation complex on the lysosomal membrane. Macroautophagy 
(autophagy) involves the formation of the autophagosome, a double-
membraned organelle that forms around cytosolic cargo and 
subsequently degrades the cargo by lysosomal fusion [44].
Like other cells, neurons too accumulate protein aggregates and 
damaged organelles such as mitochondria that must be degraded by 
autophagy to maintain cellular homeostasis. However, neurons are post-
mitotic cells that are highly polarized with both dendritic and axonal 
compartments, which can extend over distances many times greater 
than their cell soma. Consequently, neurons require motor proteins 
to actively supply proteins and organelles to these distal processes 
and to drive the transport of signaling molecules and degradative 
compartments back to the cell body. Neurons also have high energetic 
demands due to their elaborate morphologies and their need to maintain 
active electrochemical signaling. They require efficient recycling of 
proteins and organelles at the synapse, as well as throughout the axon, 
dendrites, and cell soma, making autophagic degradation particularly 
crucial in neurons. Autophagy is also required for neuronal development 
and the maintenance of axonal homeostasis [45,46].
The defective autophagy induces protein aggregation and 
neurodegeneration [46,47]. Although autophagy is efficient in younger 
neurons, autophagy proteins such as beclin-1, Atg5, and Atg7 decline 
with age [48] potentially contributing to the late onset of many NDs [49].
Mitophagy
Neurons are highly dependent on mitochondrial metabolism for their 
high-energy demands. As such, the mitochondrial network needs 
to be in perfect working order. Moreover, the unique morphology of 
neurons, with their axons and dendrites, means that mitochondria 
must be recruited to distant parts of the cell through axonal transport 
to satisfy energy demands at those sites. Consequently, neurons are 
vulnerable to defects in axonal trafficking. Finally, due to the post-
mitotic state of neurons, cellular division cannot act as a diluting factor 
for components accumulating within the cell: This means that neurons 
require an adequate “cleaning system” to eliminate any damaged or 
unwanted mitochondria that could be a source of ROS or an inducer of 
programmed cell death. Given their essential role in neuronal viability, 
any alterations in mitochondrial function could lead to neuronal death, 
thus explaining why mitochondrial dysfunction has been linked to 
numerous neurodegenerative disorders [50].
When mitochondria become “old” or damaged and are no longer able 
to efficiently produce energy, they are eliminated from the cells by a 
process known as mitophagy, where autophagosomes engulf and 
remove them from the internal cell environment, and they are then 
degraded by lysosomes [51].
Mitophagy regulates the number of mitochondria according to 
metabolic demands, and it also serves as a quality control mechanism 
to eliminate damaged mitochondria. Mitophagy is preceded by 
mitochondrial fission, which divides mitochondria into pieces for 
engulfment, followed by disposal [52].
Mitophagy is the only known pathway through which whole 
mitochondria can be selectively eliminated. This mechanism was 
first characterized in yeast in 2004 [53]. Later, in 2006, the term 
“mitophagy” was used by LeMaster Group in relation to mammalian 
cells; they showed that depolarized mitochondria localize inside light 
chain 3 (LC3)-GFP-labeled autophagosomes before being completely 
degraded [54].
Mitophagy follows a general pattern involving a receptor-mediated 
mechanism, whereby the receptors physically connect the 
mitochondria to be eliminated with LC3-II, the main component of the 
autophagosomal membrane. This connection is established through 
the LC3-interacting region (LIR) present in all receptors [55]. The 
nature and origin of mitophagy receptors can vary depending on the 
type of mitophagy; some receptors are proteins or lipids localized in 
the mitochondrial membrane, while others are non-mitochondrial 
proteins that recognize and simultaneously bind ubiquitinated chains 
on the mitochondrial surface and LC3-II on the nascent autophagosome 
structure. These receptors contain both the LIR motif to bind LC3 and 
the ubiquitin-binding domain to bind ubiquitin (UB) chains on the 
targeted mitochondria [55].
Mitophagy is a part of the normal cellular turnover of mitochondria and 
is essential to keep cells healthy. If this process is impaired or fails, it 
leads to the accumulation of dysfunctional mitochondria, which induces 
oxidative stress within a cell, leading to cellular degeneration. The 
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role of mitochondrial dysfunction and the impairment of mitophagy 
in disease and pathology is starting to be elucidated, highlighting 
the importance of finding therapeutic strategies that help promote 
mitochondrial clearance and quality control [51,56].
Mechanistic view of mitophagy
In mitophagy, the enzymes E3 ubiquitin ligases such as parkin (also 
known as PARK2) and the protein kinase PTEN-induced putative kinase 
1 (PINK1) collaborate to ubiquitylate or “tag” mitochondrial membrane 
proteins of damaged mitochondria with ubiquitin, a 7.5 kDa regulatory 
protein. This tagging promotes the clearance of these poorly functioning 
mitochondria from normal healthy cells. During the mitophagy process, 
the initiating event is the loss of the mitochondrial membrane potential 
of damaged mitochondria (and eventually the opening of mtPTPs), 
which leads to the accumulation of the PINK1 at the outer membrane 
of the mitochondrion, which in turn phosphorylates parkin, Mfn2, and 
other proteins. Parkin is a cytosolic E3-ubiquitin ligase that is selectively 
recruited to damage mitochondria. Activated parkin ubiquitinates the 
outer mitochondrial membrane proteins. Ubiquitin-tagged mitochondrial 
proteins, in turn, assist in the recruitment of autophagosomal membranes 
to mitochondria and trigger their fragmentation and degradation [57]. 
Impaired mitophagy may contribute to the decline of mitochondria 
function leading to the aging phenotype [58].
In addition to classical PINK1/parkin-related mitophagy, other 
mitophagy receptors have been discovered, including AMBRA1, 
FUNDC1, and Nix/BNIP3L in mammals. AMBRA1 can bind to LC3 and 
induce mitophagy in either a parkin-dependent or parkin-independent 
manner [59]. FUNDC1 is a mitochondrial outer membrane protein that 
can regulate mitochondrial fusion/fission (Drp1 and Opa1) to induce 
mitophagy in hypoxic conditions [60,61].
MITOPHAGY AND AD
Although the origin, progression, and heterogeneity of NDs differ, 
these disorders are characterized by common features at the 
molecular level. These include: (i) Accumulation of aggregated 
misfolded proteins; (ii) impairment of degradative processes including 
autophagy and the ubiquitin-proteasome system; (iii) oxidative stress; 
(iv) neuroinflammation; and (v) impaired mitochondrial function 
comprising mitochondrial dynamics, trafficking, and turnover [50].
AD is the most common form of dementia and is characterized by 
a progression from episodic memory problems to severe cognitive 
decline and complete dependence of the patient on caregivers. The 
disease-defining histopathological abnormalities, extracellular 
deposits of amyloid β-peptide (Aβ) and intraneuronal accumulation 
of hyperphosphorylated Tau (Tau) are the primary disease defining 
features  occurring in the entorhinal cortex and hippocampus [62,63].
A widely documented abnormality in neuronal physiology that occurs 
before the onset of discernable cognitive deficits in those who develop 
AD is impaired glucose utilization and mitochondrial abnormalities 
in AD, elucidating the underlying molecular mechanisms and cellular 
consequences of mitochondrial deficits. The mitochondrial cascade 
hypothesis states that each individual’s genetically determined and 
environmentally influenced mitochondrial function are primary factors 
influencing late-onset AD pathology [64].
Increasing evidence suggests that inhibition of the clearance of 
damaged mitochondria, along with concurrent increases in oxidative 
stress levels, results in the accumulation of dysfunctional neurons in 
AD. To be removed by mitophagy, the autophagosome containing the 
mitochondrion must fuse with a lysosome to form autolysosomes in 
which proteases degrade the mitochondrion. Neurons exhibiting an 
abnormal accumulation of autophagosomal vacuoles are a prominent 
feature in AD, and their accumulation may result from lysosomal 
dysfunction (elevated pH), perhaps secondary to dysregulation of 
neuronal Ca2+ homeostasis [65,66]. The undegraded dysfunctional 
mitochondria accumulate in the soma which may result from the 
combination of local lysosome dysfunction and impaired mitochondrial 
transport [67]. The impairment of lysosomal function in healthy cells 
results in neuronal phenotypes like those in AD [67].
Mitophagy- and mitochondrial dynamics-related proteins affected in 
AD include those involved in mitochondrial fission and fusion (Drp1 
and mitofusin), mitochondrial biogenesis (PGC-1α), and mitochondrial 
responses to bioenergetic and oxidative challenges (SIRT3 and 
SIRT1) [68,69]. Mitochondrial fission and fusion are controlled 
by specialized proteins such as Fis1 and Drp1 [70,71] and Opa1, 
respectively [72]; the levels of each of these proteins determine the 
amount of fission and fusion occurring. Before fission, damaged DNA 
and proteins are segregated to one side of the mitochondrion such that, 
on fission, one of the “daughter” mitochondrion contains damaged 
molecules and is targeted for mitophagy, while the other daughter 
mitochondrion is now pristine [73]. Cell culture and animal models of 
AD have demonstrated excessive fission of mitochondria concomitant 
with an accumulation of dysfunctional mitochondria, possibly as the 
result of lysosomal dysfunction [74]. Some studies have demonstrated 
the increased levels of Drp1 in the brains of AD patients and mice [75].
Analyses of postmortem brain tissue from AD patients and age-matched 
control subjects have revealed reduced expression of genes related 
to mitochondrial biogenesis including PGC-1α, TFAM, and NRF2 [76]. 
Further, Beclin1, which is necessary for the initiation of autophagy, has 
been shown to be reduced in the brains of patients with AD, and the 
reduction of beclin1 leads to decreased autophagy, the accumulation of 
Aβ peptides, and neurodegeneration in mouse models of AD [77].
Amyloid β and mitophagy
The formation of extracellular senile plaques containing Aβ starts 
with the processing of amyloid precursor protein (APP) by β- and 
γ-secretases; some of the resulting Ab peptides can spontaneously 
aggregate to form oligomers and subsequently insoluble fibrils in a 
process called amyloidogenesis. These oligomeric Ab’s are the precursors 
of the insoluble amyloid fibrils and are considered responsible for the 
neurotoxicity present in AD. This amyloidogenic process can occur 
both externally at the plasma membrane, where APP localizes, and 
inside the cell, in the membranes of different cellular compartments 
where the APP along with the b- and g-secretases is also present. 
These intracellular compartments include endosomes, the trans-Golgi 
network, the endoplasmic reticulum, lysosomes, autophagosomes, 
multivesicular body, and mitochondria [78]. Thus, Aβ can be found both 
extracellularly and intracellularly where it can interfere with different 
cellular pathways. The endosomal system participates at different levels 
in the production of Aβ. These include the processing of APP to Aβ at the 
endosomal membrane, the internalization of external Aβ by endocytosis, 
and the intracellular trafficking and secretion of Aβ to the outside of the 
cell. Changes in the endosomal system have been observed in AD, and 
several proteins regulating this pathway shown to be altered, thereby 
affecting the regulation, sorting, trafficking, and secretion of endosomal 
vesicles. As a result, levels of intracellular Aβ increase and promote 
further endosomal dysfunction as a consequence [79].
In AD, mitochondrial dysfunction promotes amyloid production 
through oxidative stress production. Oxidative stress increases 
γ-secretase activity by a mechanism involving covalent modification 
of the γ-secretase complex protein nicastrin by the membrane 
lipid peroxidation product 4-hydroxynonenal [80]. A major source 
of 4-hydrox-ynonenal is arachidonic acid, a lipid enriched in 
mitochondrial membranes. Together, accumulating evidence suggests 
that amyloidogenic APP processing in late-onset AD occurs due to an 
increased generation of ROS by dysfunctional mitochondria in neurons.
Tau and mitophagy
Microtubule-associated protein Tau is another predominant player in 
AD. Microtubules are a component of the cellular cytoskeleton on which 
mitochondria, lysosomes, and other organelles are transported. Tau 
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binds and stabilizes microtubules, but when Tau is hyperphosphorylated 
it detaches from and thereby destabilizes microtubules resulting 
in their depolymerization. The accumulation of pTau aggregates 
and fibrils in the cell bodies and neurites of degenerating neurons is 
strongly correlated with cognitive deficits in AD [81].
Studies of experimental models have provided evidence that 
mitochondrial dysfunction can result in pTau, microtubule 
depolymerization, and neurofibrillary tangle-like pathology. AD- like 
pTau occurs in hippocampal neurons with chronically elevated Ca2+ 
levels due to exposure to glutamate, a condition in which mitochondrial 
function is impaired. By initiating membrane lipid peroxidation, 
ROS generated by mitochondria may also promote pTau and its 
aggregation [82]. Similarly, the deletion of AFG3L2, a protease that 
processes misfolded proteins in the inner mitochondrial membrane, 
leads to mitochondrial network fragmentation, defective anterograde 
mitochondrial transport, and subsequent Tau hyperphosphorylation in 
neurons [83].
Further, a basic cellular metabolite, NAD+ exists in all living cells 
including brain cells, where it plays fundamental roles in neuroplasticity 
and cellular stress resistance. In cell metabolism, NAD+ and its 
reduced form NADH are necessary for glycolysis, tricarboxylic acid 
cycle, OXPHOS, and ATP production. As neurons consume relatively 
large amounts of energy, they are extremely sensitive to decreased 
NAD+ levels as well as impairment of ATP production. Furthermore, 
NAD+ affects neuronal health and survival through the regulation of 
the balance between mitochondrial biogenesis and mitophagy, which 
are controlled by the NAD+/SIRT1– PGC-1a pathway and the DAF-
16/FOXO3 pathway [84]. Decreased NAD+ levels can compromise 
mitophagy and trigger the accumulation of misfolded proteins leading 
to neuronal death [85]. Mitochondria play a part in the regulation of 
diverse physiological functions by providing energy for the majority 
of intracellular processes necessary for vital functions [86], and its 
optimum functioning is crucial for overall cell survival. Mitochondrial 
dysfunction decreases neuronal glucose which causes a decrease in Ach, 
ChAT, and ATP and increase in AchE. These lead to oxidative damage, 
DNA damage, and neuroinflammation after that it causes learning and 
memory impairment and neurotoxicity [87].
CONCLUSION
Accumulation of dysfunctional mitochondria and impairment in 
neuronal autophagy leading to impaired mitophagy are prominent 
features of AD. Although it remains to be determined if the presence of 
dysfunctional mitochondria is a consequence of inefficient mitophagy, 
or whether mitochondrial dysfunction is an early event preceding 
impairment of the autophagy/mitophagy systems, the concept of 
mitophagy and therapeutic viability of mitophagy is yet to be revealed 
as it holds immense potential.
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